Microbiome Modulators Slowly Nurture Investor Confidence
Microbiotica Raises £50m Series B
Executive Summary
Once deemed an intimidating and risky space, microbiome modulator firms are slowly winning over investors as robust clinical data surface, with one company, Microbiotica, recently hitting an EU financing record.
You may also be interested in...
European Biomanufacturing SPAC Launched, Backed By Former Sanofi-Aventis CEO Le Fur
EureKING hopes to help develop and manufacture novel cell and gene therapies and live biotherapeutics, among other types of biologics, through a number of strategic acquisitions.
Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.